-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, the State Food and Drug Administration issued an announcement stating that in accordance with Article 83 of the Drug Administration Law of the People's Republic of China and other relevant regulations, the State Drug Administration organized a post-marketing evaluation of Lianbizhi injection
.
After evaluation, the State Food and Drug Administration decided to stop the production, sales and use of Lianbizhi injection in China from now on, and cancel the drug registration certificate
.
For products that have been marketed, the holder of the drug marketing authorization is responsible for the recall, and the recalled products are supervised and destroyed by the local provincial drug supervision and administration department or take other measures such as harmless treatment in accordance with the law
Attachment: Lianbizhi Injection Variety Information Sheet
Attachment: Lianbizhi Injection Variety Information Sheet